VDAC1 and systemic lupus erythematosus: Novel compounds that interact with VDAC1 and inhibit its oligomerization, such as VBIT-4 and VBIT-12, have demonstrated efficacy in mitigating the pathophysiology of several conditions, including type-2-diabetes [64], lupus [62], colitis [61], Alzheimer’s disease [65], acute liver injury [66,67], spinal cord injury [68], and COVID-19 [69].